We're the intersection of engineering and medicine.
Gemstone Bio's Story
Gemstone Biotherapeutics LLC was founded by Gamma 3 LLC and established in Baltimore, Maryland in 2013 as a pre-clinical research and development initiative built on the foundation of an exclusive IP license with Johns Hopkins University. Gemstone is dedicated to discovering, developing, and acquiring advanced technologies that are patient-focused and deliver broad and targeted wound care solutions.
Core technologies at Gemstone include biosynthetic scaffolds and therapeutics that are geared towards wound healing.
The Gamma 3 Initiative was founded in 2012 and focuses on identifying, acquiring and incubating high-value IP by partnering with academic institutions, inventors and entreprenuers to advance biomedical technology and create commercial oppurtunities.
Gemstone Bio's Team
CEO, Leadership Team
Mr. Davis founded Gemstone in 2013 with business partner Dave Oros and the Gamma 3 Investment Initiative, of which Mr. Davis is a Managing Partner. He brings over thirty years of executive management experience and entrepreneurial and business leadership to Gemstone. Previous to Gemstone, Mr. Davis was the President and Vice Chairman of Aether Systems and CEO of Avatech Solutions.
Sharon Gerecht, Ph.D.
Inventor, Director, and Lead Advisor
Professor Gerecht’s laboratory utilizes engineering fundamentals to study the interactions between stem cells and their microenvironment and applies this research to guide vascular differentiation and develop biomaterials for tissue regeneration. Dr. Gerecht received her Ph.D. in Bioengineering from the Israel Institute of Technology and was a postdoctoral researcher at MIT and the Israel Institute of Technology.
Laura E. Dickinson, Ph.D.
Dr. Dickinson received her Ph.D. in Chemical and Biomolecular Engineering from The Johns Hopkins University. For her PhD, she developed biomaterials that recapitulated the cellular microenvironment to study angiogenesis and cancer progression. She also contributed to the development of Gemstone Bio’s biosynthetic scaffold technology. She has an extensive research background in chemical engineering, tissue engineering, and bionanotechnology. Previous to Gemstone, she was a postdoctoral researcher in biophysics at the Delft University of Technology. Laura joined Gemstone as the Director of Research and Development, where she manages research and development efforts from design to validation and oversees regulatory affairs.
Matthew J. Davenport
Mr. Davenport graduated from The Johns Hopkins University with a BS/MSE in Chemical and Biomolecular Engineering. At Johns Hopkins, Mr. Davenport worked in the lab of Dr. Sharon Gerecht and was a key researcher in the development of Gemstone’s core technology. Mr. Davenport brings a vast background in material science, bioengineering, and downstream processing to Gemstone. His past research experiences include Myriant Technologies and the European Molecular Biology Laboratories (EMBL).
Susan Volk, Ph.D., V.M.D
Associate Professor of Small Animal Surgery, School of Veterinary Medicine, University of Pennsylvania
Peter Abadir, M.D.
Assistant Professor of Geriatric Medicine and Gerontology at JHMI.
Jeremy Walston, M.D.
Raymond and Anna Lublin Professor of Geriatric Medicine at JHMI; Co-Director of the Biology of Healthy Aging Program in the Division of Geriatric Medicine and Gerontology.